24 results
424B5
ZYME
Zymeworks Inc.
3 May 24
Prospectus supplement for primary offering
4:17pm
in the applicable prospectus supplement, on a firm commitment basis. This prospectus may be used in connection with any offering of our securities through any … the standby underwriters a commitment fee for the securities they commit to purchase on a standby basis. If we do not enter into a standby underwriting
424B5
ZYME
Zymeworks Inc.
3 May 24
Prospectus supplement for primary offering
4:11pm
or, if indicated in the applicable prospectus supplement, on a firm commitment basis. This prospectus may be used in connection with any offering of our … as standby underwriters. We may pay the standby underwriters a commitment fee for the securities they commit to purchase on a standby basis. If we do not enter
S-3ASR
ZYME
Zymeworks Inc.
2 May 24
Automatic shelf registration
4:34pm
in the applicable prospectus supplement, on a firm commitment basis. This prospectus may be used in connection with any offering of our securities through any … pay the standby underwriters a commitment fee for the securities they commit to purchase on a standby basis. If we do not enter into a standby
8-K
EX-99.1
ZYME
Zymeworks Inc.
2 May 24
Zymeworks Provides Corporate Update and Reports First Quarter 2024 Financial Results
4:07pm
to enter multiple Phase 1 trials in the coming 24 months, our commitment to advancing innovative solutions remains evident, with more preclinical data
8-K
EX-99.1
rf9wt0w822sf
6 Mar 24
Zymeworks Reports Fourth Quarter and Full Year 2023 Financial Results
4:13pm
8-K
EX-99.1
sks358k vtsb
4 Jan 24
Zymeworks Outlines Strategic Priorities and Outlook for 2024 and 2025
6:31am
8-K
EX-99.1
qx7hvhdtzubg0 9dw
26 Dec 23
Zymeworks Announces $50 Million Private Placement to EcoR1 Capital
8:09am
8-K
EX-99.1
ruhj43f op7og3pkj
16 Oct 23
Zymeworks Announces New Director Nominee
4:45pm
8-K
EX-99.1
zoi60fo7392wjk
18 May 23
Zymeworks Announces Departure of Neil Klompas, President and Chief Operating Officer
8:40am
8-K
EX-10.1
da77keu anx
16 May 23
Entry into a Material Definitive Agreement
8:30am
424B5
wlsjh211
8 May 23
Prospectus supplement for primary offering
5:18pm
DEF 14A
t3umu
25 Nov 22
Definitive proxy
6:16am
8-K
EX-99.1
h14th t14on
19 Oct 22
Jazz Pharmaceuticals and Zymeworks Announce Exclusive License Agreement to Develop and Commercialize Zanidatamab, a HER2-Targeted Bispecific Antibody
6:26am
8-K12B
EX-3.4
1pio 0jzp1sqn
13 Oct 22
Notification of registration of securities
7:24am